Acute Myeloid Leukemia, Adult
Welcome,         Profile    Billing    Logout  
 176 Companies   232 Products   232 Products   108 Mechanisms of Action   9 Trials   1978 News 


«12...1112131415161718192021...4142»
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Enrollment change, Trial primary completion date:  Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (clinicaltrials.gov) -  Feb 12, 2015   
    P2,  N=41, Active, not recruiting, 
    Active, not recruiting --> Completed N=90 --> 41 | Trial primary completion date: Dec 2015 --> Feb 2014
  • ||||||||||  lenalidomide / Generic mfg.
    Enrollment open, Trial initiation date, Combination therapy:  Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML (clinicaltrials.gov) -  Feb 12, 2015   
    P1,  N=56, Recruiting, 
    N=90 --> 41 | Trial primary completion date: Dec 2015 --> Feb 2014 Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015
  • ||||||||||  decitabine / Generic mfg.
    Enrollment closed:  AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Feb 12, 2015   
    P1,  N=54, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Oct 2014 --> Jan 2015 Recruiting --> Active, not recruiting
  • ||||||||||  CYAD-01 / Celdara Medical, Celyad Oncology
    Trial initiation date, Trial primary completion date, Metastases:  Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) -  Feb 10, 2015   
    P1,  N=21, Not yet recruiting, 
    Not yet recruiting --> Suspended Initiation date: Oct 2014 --> Feb 2015 | Trial primary completion date: Oct 2015 --> Feb 2017
  • ||||||||||  CWP291 / JW Pharma
    Enrollment change, Trial primary completion date:  Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (clinicaltrials.gov) -  Feb 10, 2015   
    P1,  N=60, Recruiting, 
    Initiation date: Oct 2014 --> Feb 2015 | Trial primary completion date: Oct 2015 --> Feb 2017 N=48 --> 60 | Trial primary completion date: Dec 2014 --> Dec 2015
  • ||||||||||  busulfan / Generic mfg., etoposide IV / Generic mfg.
    Enrollment closed:  Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen (clinicaltrials.gov) -  Jan 28, 2015   
    P1,  N=48, Active, not recruiting, 
    N=50 --> 70 Recruiting --> Active, not recruiting
  • ||||||||||  volasertib (NBL-001) / Oncoheroes, Notable Labs
    Enrollment closed, Combination therapy:  Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) -  Jan 16, 2015   
    P1/2,  N=164, Active, not recruiting, 
    Phase classification: P=N/A --> P2 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Trial primary completion date, Combination therapy:  Study of VELCADE (clinicaltrials.gov) -  Jan 12, 2015   
    P1/2,  N=55, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2013
  • ||||||||||  azacitidine / Generic mfg.
    Trial primary completion date:  Piaza: Non-interventional Study With Azacitidin (Vidaza (clinicaltrials.gov) -  Jan 8, 2015   
    P=N/A,  N=150, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jan 2015 Trial primary completion date: Jul 2014 --> Dec 2014
  • ||||||||||  Enrollment closed, Trial primary completion date, Combination therapy:  Study of VELCADE (clinicaltrials.gov) -  Jan 8, 2015   
    P1/2,  N=55, Active, not recruiting, 
    Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015
  • ||||||||||  MK-2206 / Merck (MSD)
    Trial completion, Enrollment change, Trial primary completion date:  AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 7, 2015   
    P2,  N=19, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015 Active, not recruiting --> Completed | N=43 --> 19 | Trial primary completion date: Oct 2012 --> Oct 2013
  • ||||||||||  daunorubicin / Generic mfg., cyclophosphamide / Generic mfg., decitabine / Generic mfg.
    Enrollment closed:  Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms (clinicaltrials.gov) -  Dec 24, 2014   
    P2,  N=450, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Beleodaq (belinostat) / Aurobindo, Assertio
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (clinicaltrials.gov) -  Dec 24, 2014   
    P1,  N=56, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=33 --> 56 | Trial primary completion date: Aug 2011 --> Mar 2013
  • ||||||||||  buparlisib (AN2025) / Adlai Nortye
    Enrollment change, Trial primary completion date:  SIGNATURE: BKM120 for Patients With PI3K-activated Tumors (clinicaltrials.gov) -  Dec 10, 2014   
    P2,  N=140, Recruiting, 
    Trial primary completion date: Sep 2017 --> May 2015 N=70 --> 140 | Trial primary completion date: Jul 2017 --> May 2015